CASE STUDIES / Better Investment & Management

Samsung C&T's Consultation on Acquisition of Farm in Indonesia

Samsung C&T Website
  • M&A

  • Advisory

  • Investment

KEY STATS

  • 192.6 billion won (KRW)

    162.5M USD Investment amount

The farm, acquired by Samsung C&T, is located on Indonesia's Sumatra Island, with a total area of 24,000 hectares, or 40 percent of the city's area.

Samsung C&T's acquisition of a farm farm farm was aimed at gaining ground in this field as the palm oil consumption market grew at an average rate of 12 percent over the past 10 years, and countries around the world are sharply strengthening their renewable energy businesses, including biodiesel, to secure alternative energy sources in response to high oil prices and reduce greenhouse gas emissions.

The farm, acquired by Samsung C&T, is located on Indonesia's Sumatra Island, with a total area of 24,000 hectares, or 40 percent of the city's area, and also has facilities that can produce more than 100,000 tons of palm oil a year, which is a raw material for bio-diesel and edible oil.

Samsung C&T plans to supply palm oil produced by these farms to biodiesel-related companies around the world. Starting with such bio-material supply projects, Samsung C&T plans to expand its business by step by step by securing additional farms and expanding refining facilities, establishing its own biodiesel production system, and strengthening logistics and global sales networks.

As of December 2019, 109 subsidiaries (six in Korea and 103 overseas) were listed in Korea, and Samsung Biologics was listed in Korea. It owns 5.0% of Samsung Electronics and 19.3% of Samsung Life Insurance.

It was established as Cheil Industries in 1963 and changed its name to Samsung C&T when it merged with Samsung C&T in September 2015.

The business sectors are divided into the construction sector, the commercial sector (resource development and international trade), the fashion sector, the resort sector (Everland, golf course, food materials distribution, etc.) and the biosimilar business.

XS
SM
MD
LG